Cyrano Therapeutics is a biotechnology company focused on the development of therapeutics for diseases of the nose and sinuses. The company's lead product candidate is aimed at addressing chronic rhinosinusitis, a condition that affects millions of people worldwide.

Cyrano Therapeutics

Cyrano Therapeutics has developed a unique, proprietary intranasal formulation to restore function in patients with a chronic loss of taste and smell.  This is a condition affecting more than 40 million people in the US and Europe and millions more across the world, having a significant impact on safety, quality of life and well-being.  Currently no marketed pharmaceutical therapy exists and aside from the Cyrano product, none are in the pipeline.
 
The Cyrano formulation (CYR-064) has been tested with success in a 92 patient pilot study and the Company is currently enrolling patients in a Phase 2 placebo-controlled double-blind randomized trial at 14 sites in the United States with data readout expected in Q1'25.

Additional information can be found on our website www.cyranotherapeutics.com





 


Metric
Company Name	Cyrano Therapeutics
Symbol
MSH ID	COM:CYRANOTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	6
Website	cyranotherapeutics.com
LinkedIn	cyrano-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CYRANOTHERAPEUTICS

Cyrano Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue